Search

Selenium deficiency has been suggested by several studies to be associated with cancer risk. We conducted a case-control study in Szczecin, a region of northwestern Poland, on 86 cases of lung cancer, 87 cases of laryngeal cancer and an equal number of healthy controls. We studied the serum level of selenium and genotypes for four variants in four selenoprotein genes (GPX1, GPX4, TXNRD2 and SEP15) and the odds of being diagnosed with lung or laryngeal cancer. Among lung cancer cases, the mean selenium level was 63.2 µg/l, compared to a mean level of 74.7 µg/l for their matched controls (p 80 µg/l) was associated with an odds ratio of 0.10 (95% CI 0.03 to 0.34; p = 0.0002) for lung cancer and 0.24 (95% CI 0.10 to 0.59; p = 0.002) for laryngeal cancer. In four selenoproteins studied here we found a modest associations of genetic variants in GPX1 and GPX4 with lung and TXNRD2 with laryngeal cancer risk. We analyzed iron (Fe) level in serum of 77 lung cancer patients and 77 matched controls. We did not find difference in mean Fe level between cases and controls (1053.05 µg/l and 1059.39 µg/l). However, we found that Fe level in the lowest and highest quartiles was associated with a significant lung risk enhancement when compared to a serum Fe level in the middle quartiles (OR 0.3, p 0.02). We also observed that the relationship between the level of Fe and Se could be an important factor for lung cancer risk.

Recent studies indicate that the selected micro-and macro-elements and vitamins may significantly influence the risk of cancer. Folic acid is a vitamin B which plays an important role in several processes in organism. Folates are important cofactors in the transfer and utilization of one-carbon-groups and play a key role in the remethylation of methionine thus providing essential methyl groups for numerous biological reactions. Furthermore, folates donate one-carbon units in the process of DNA-biosynthesis with implications for the regulation of gene expression, transcription, chromatine structure, genomic repair and genomic stability. Deficiency of folic acid has been reported to be associated with numerous disorders, including heart disease, stroke and cancers. The MTHFR gene produces a key enzyme in folate metabolism which catalyses the reactions essential for nucleotide biosynthesis and DNA methylation. The aim of study was to analyze an association of folic acid concentrations and genetic variants in the MTHFR gene with breast cancer risk in patients with BRCA1 mutation. Study group consisted of 155 breast cancer patients and 155 healthy women from the paired control group matched to cases by year of birth, cancer family history, adnexectomy, smoking. From all individuals blood sample was collected and from cancer cases was taken before treatment. Folic acid concentration was quantitatively measured in blood plasma by HPLC chromatography (Flexar HPLC, Perkin Elmer). Two functional SNPs in the MTHFR gene, 677 C>T (rs1801133) and 1298 A>C (rs1801131), both associated with reduced enzyme activity, have been tested by TaqMan on LightCycler 480.(Roche Diagnostic). Individuals were divided into four quartiles depending on folic acid concentration and number of cases and controls in each quartile was compared. Analysis was made depending on menopausal status defined as ≤ 50 and >50 years old. In a group of >50 years old, individuals classified in the first quartile ( 50 and ≤50 years) revealed: - for carriers of 1298 nCC and ≤50 years old significantly lower risk of breast cancer in individuals classified between 16,6-31,88 μmol/l in comparison to patients with lower and higher folate level. - for carriers of 677 CC and ≤50 years old lower risk of breast cancer in individuals classified between 19,86-32,02 μmol/l than patients with lower and higher folate level. - for carriers of 677nCC and ≤50 years old significantly lower risk of breast cancer in individuals classified between 5,94-14,8 μmol/l in comparison to patients with higher folate level. - for carriers of 1298 AA and >50 years old lower risk of breast cancer in individuals classified in the first quartile (50 years old lower risk of breast cancer in individuals classified in the first quartile (50 years old lower risk of breast cancer in individuals classified in the first quartile (50 years old lower risk of breast cancer in individuals classified in the first quartile (50 years.